PanTher Strengthens Cancer Drug Delivery Platform With New Patents and Appointment of Oncology Veteran
Key Points
- PanTher secured two new U.S. patents protecting its Sagittari implantable drug delivery platform into the 2040s
- Lead candidate PTM-101, an absorbable paclitaxel implant for pancreatic cancer, is in Phase 1b expansion with topline results expected in the first half of 2027
- Oncology veteran Tim Clackson, PhD, was appointed executive chair of PanTher's board of directors
AUSTIN, Texas, November 16, 2026 – PanTher Therapeutics has secured two new U.S. patents covering its implantable drug delivery technology for cancer treatment, expanding intellectual property protection for its lead pancreatic cancer program and opening the door to additional drug and tumor indications. The company also appointed biotechnology executive Tim Clackson, PhD, as executive chair of its board of directors to help guide clinical development and corporate growth.
The patents, issued by the U.S. Patent and Trademark Office, strengthen protection for PanTher’s Sagittari platform into the 2040s, excluding potential extensions. One patent covers multilayered, biodegradable implants designed to release chemotherapy directly toward pancreatic tumors while limiting exposure to surrounding healthy tissue. The second provides broader, drug-agnostic protection for implantable systems capable of delivering different active pharmaceutical ingredients to targeted tissue, supporting the platform’s potential application across multiple solid tumor types.
PanTher’s lead candidate, PTM-101, is an absorbable paclitaxel-containing implant being evaluated in a Phase 1b clinical trial in patients with non-metastatic pancreatic ductal adenocarcinoma (PDAC). Designed for placement at the tumor site during a routine staging laparoscopy, the implant provides sustained local drug delivery for approximately six weeks. The approach is intended to expose the tumor to high concentrations of chemotherapy while minimizing systemic exposure. The study has completed dose escalation and moved into its expansion phase, with topline results expected in the first half of 2027.
The company also announced the appointment of Clackson, who brings more than 30 years of biotechnology and oncology drug development experience. He most recently served as CEO of IDRx, which was acquired by GSK in a transaction valued at up to $1.15 billion. His previous leadership positions include roles at Theseus Pharmaceuticals, Xilio Therapeutics and ARIAD Pharmaceuticals. In his new position, Clackson will work with management and the board on corporate strategy, clinical development, financing and partnership opportunities.
PanTher CEO and Co-founder Laura Indolfi, PhD, says the patent awards and leadership appointment strengthen the company’s position as it advances its implantable drug delivery technology beyond its initial pancreatic cancer application. Clackson says the company’s clinical progress is helping establish the platform’s potential and support its next phase of development. Beyond PTM-101, PanTher is developing additional polymer-based drug formulations for other solid tumor indications.
For more information, visit www.panthertx.com.
Total Page Views: 1

















